AI predicts the probability of success of clinical trials
CompanyInsilico Medicine, Pak Shek Kok, Hong Kong SAR of China
To optimize drug studies in the clinical phase, Insilico Medicine has developed the AI-based platform inClinico. To predict the feasibility and probability of success (PoS) of individual clinical studies, the AI relies on a huge data set that, in addition to relevant OMICs data on genomics, epigenomics, transcriptomics and proteomics, includes all published information and findings from past and current (pre-)clinical studies taken into account. The company uses specially developed algorithms to integrate the study-specific data. This enables the platform to carry out tailor-made studies, from planning and creating the study design to recruiting and selecting participating patients and evaluating the results. Potential drug candidates can be identified quickly and reliably and prioritized for further study. In summary, inClinico shows promise as a method for accelerating clinical drug trials that can help improve risk management and manage resources more efficiently.
inClinico. Clinical risk assessment and portfolio triage
info@insilicomedicine.com
Added on: 12-01-2023
[1] https://insilico.com/inclinico
